22 February 2021
Visiongain has published a new report on Antibiotics Market Report to 2031. According to the Visiongain analysis, the global Antibiotics market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Antibiotics market is segmented by type and mechanism. By type, the market is categorized as (Cephalosporins, Macrolides, Tetracycline, penicillin, Fluoroquinolones, Aminoglycosides), By mechanism (Cell Wall Synthesis, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA synthesis Inhibitors, Mycolic Acid synthesis inhibitors, Folic Acid synthesis inhibitors). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Antibiotics Companies. PLUS COVID-19 Recovery Scenarios.
Global Antibiotics Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. The rising demand for antibiotics to treat children with potentially fatal sepsis and pneumonia and the increasing prevalence of infectious diseases are some of the factors driving the growth of the Global Antibiotics market.
COVID-19 Impact on the Global Antibiotics Market
The COVID-19 pandemic severely affected the global economy. The pandemic had considerable impact on the antibiotics market. The use of antibiotic was significantly less, due to the COVID-19 restrictions and limited medical procedures at the hospitals. However, the unlocking phases of lockdowns gave some relief to the market players since the growth started to come to back in positive.
Increasing prevalence of` infectious diseases
According to WHO, infectious diseases are responsible for millions of fatalities, which is estimated to be around 13 million mortalities per year, one in two deaths in developing countries. Almost 90.0% of deaths are caused due to handful of infectious diseases such as pneumonia, tuberculosis, malaria, measles, and HIV. The antibiotics, also called antibacterial or antimicrobial drugs, use is increasing to prevent infections caused by strains of bacteria. In developing countries, infectious diseases are increasing rapidly; however, advancement & increasing demand for antibiotics have the potential to boost the market.
Rising demand for antibiotics to treat children with potentially fatal sepsis and pneumonia
Pneumococcal disease is caused by common bacteria (Streptococcus pneumonia), which attacks different parts of the body. The bacteria invade the lungs, and cause pneumonia; the invasive infections are serious, need hospitalization, and can lead to death. Pneumococcal disease is a leading cause of serious illness globally, the demand for an antibiotic is rising to treat children with pneumonia. According to the National Foundation for Infectious Diseases about 1.3 million persons visit emergency departments in the US each year with pneumonia and 50,000 people die from pneumonia. It is estimated that from pneumococcal pneumonia more than 150,000 hospitalizations occur each year.
Antibiotic resistance is a major threat.
The National Health Service (NHS) and health organisations across the world, are trying to reduce the use of antibiotics, for the conditions that are not serious. The overuse of antibiotics leads to reduce the effectiveness and development of "superbugs". The strains of bacteria have developed resistance to various types of antibiotics, such as methicillin-resistant Staphylococcus aureus (MRSA), Clostridium difficile (C. diff), multi-drug-resistant tuberculosis (MDR-TB) and carbapenemase-producing Enterobacteriaceae (CPE). The antibiotic resistance is serious and challenging threat to antibiotic market globally.
Pfizer Inc., Thermo Fisher Scientific Inc., Astellas Pharma, Inc, F. Hoffmann-La Roche AG, Novartis AG, Bristol-Myers Squibb Co., Bayer HealthCare AG, Merck KGaA, and Abbott Laboratories are some of the key players contributing to the growth of the global Antibiotics market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.
For instance, in July 2020, Pfizer Inc. announced pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which enable global public health need for new antibiotics due to the rapid rise of antibiotic-resistant infections. The new AMR Action Fund enables to potentially enhance pipeline for antimicrobial medicines. The Fund is a collaboration among more than 20 biopharmaceutical companies, to develop 2-4 new antibiotics to patients by 2030. The pharmaceutical companies, philanthropies, development banks, and multilateral organizations comes together to accelerate antibiotic development.
In July 2020, Boehringer Ingelheim participated in the AMR Action Fund, a collaboration of 20 companies against antimicrobial resistance. The company contributed $50 million to expedite the R&D of next-generation antibiotics.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
14 July 2021
Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.